Artiva Biotherapeutics is pioneering the development of natural killer (NK) cell-based therapies, particularly through its lead product candidate, AlloNK®. This innovative therapy is a non-genetically modified, cryopreserved NK cell treatment designed to enhance antibody-dependent cellular cytotoxicity (ADCC) when used in combination with monoclonal antibodies. AlloNK® is currently undergoing clinical trials for various conditions, including systemic lupus erythematosus (SLE) and non-Hodgkin lymphoma. The company emphasizes the accessibility of its therapies, as AlloNK® is an allogeneic, off-the-shelf product that can be administered without the need for patient-specific manufacturing, which is often complex and costly.

In addition to AlloNK®, Artiva is developing targeted CAR-NK cell therapies, which involve genetically modifying NK cells to express chimeric antigen receptors (CARs) that target specific antigens on tumor cells. This approach aims to enhance the efficacy and persistence of NK cells in treating cancers. Artiva's manufacturing platform utilizes umbilical cord blood as a source for NK cells, selected for specific genetic traits that enhance their activity. The company has established a robust manufacturing process capable of producing large quantities of NK cells, ensuring that these promising therapies can be made widely available to patients suffering from autoimmune diseases and cancers.

United States

At Artiva, our mission is to deliver to cancer patients highly effective cellular immunotherapies that are also safe and immediately accessible. Towards this end, Artiva is advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, including CAR-NK cell therapies, that leverage the company’s unique manufacturing and engineering capabilities. Artiva is headquartered in San Diego. 

Cancer

Hematologic Diseases

Immune System Diseases

Lymphatic Diseases

Artiva Biotherapeutics

B-cell malignancies

AB-101

Cell Therapies

HER2-expressing cancers

AB-201

Lupus nephritis

Systemic lupus erythematosus

<p class="font_8">AlloNK is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the ADCC effect of mAbs to drive B-cell depletion. AlloNK, as a non-genetically modified, non-targeted NK cell, is designed to utilize a mAb or NK engager for targeting, and therefore can be used in different combinations against different therapeutic targets. AlloNK is currently in clinical trials for treatment of systemic lupus erythematosus (SLE) for patients with or without lupus nephritis and in a basket investigator-initiated trial (IIT) in multiple autoimmune indications. In addition, AlloNK is being evaluated for the treatment of non-Hodgkin lymphoma, as well as in combination with Affimed’s innate cell engager acimtamig for the treatment of patients with relapsed/refractory CD30-positive lymphomas.</p>

Artiva Biotherapeutics

Company Details